The Substandard and falsified medicines in the Democratic Republic of the Congo: Situational analysis and future perspectives
Orapuh Journal · 15.06.2026 · 7 (3) · e1422
DOI: 10.4314/orapj.v7i3.22 ↗Kurz gefasst
Fachartikel in der Zeitschrift Orapuh Journal, online erschienen am 15.06.2026. Verfasst von Ntambwe und 9 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
The circulation of counterfeit medicines in the Democratic Republic of the Congo (DRC) and elsewhere is driven by several factors, including regulatory weaknesses, inadequate inspections, and porous borders. This issue is frequently highlighted in case reports and scientific publications, demonstrating the link between regulatory capacity—particularly the maturity level of the National Regulatory Authority (NRA)—and the prevalence of substandard and falsified medicines.
Purpose
To assess the extent of counterfeit medicines in the DRC and propose future perspectives.
Methods
Publications related to counterfeit medicines were collected from databases such as ScienceDirect, PubMed, Google, Google Scholar, ACOREP, the World Health Organization (WHO), websites of major organizations, case reports, and alerts. Searches were conducted using the keywords “falsified,” “substandard,” “counterfeit,” and “alert” (in both English and French). References were managed using Zotero software and analyzed through a structured literature review flowchart. Inclusion criteria comprised articles published between 2010 and 2025, including case reports, alerts, and study summaries focusing on the prevention, detection, and response to counterfeit medicines for human use in the DRC or other low- and middle-income countries.
Results
Of the 238 articles and documents identified, 62 met the inclusion criteria. The average prevalence of counterfeit medicines in Africa was estimated at 18.7% (range: 12.9%–24.5%), with 34.6% classified as unregistered. In the DRC, the consolidated average prevalence rates were 22.4% for counterfeit medicines, 22.2% for substandard medicines, and 35% for unregistered medicines.
Conclusion
The Congolese Pharmaceutical Regulatory Authority (ACOREP) has not yet achieved WHO maturity level 3 (ML3) in accordance with good regulatory practices. The Congolese government is therefore encouraged to strengthen its commitment to establishing a robust and deterrent national regulatory system (NRA) to combat the circulation of counterfeit medicines, particularly given the high proportion (approximately 35%) of unregistered products
Zitieren
APA
Ntambwe, M., N., Kabamb, D, K., Mana, D., K., Marini, R, D., Mbinze, & J, K. (2026). The Substandard and falsified medicines in the Democratic Republic of the Congo: Situational analysis and future perspectives. Orapuh Journal, 7(3), e1422. https://doi.org/10.4314/orapj.v7i3.22
Vancouver
Ntambwe, M. N, Kabamb, D K, Mana, D. K, et al. The Substandard and falsified medicines in the Democratic Republic of the Congo: Situational analysis and future perspectives. Orapuh Journal. 2026;7(3):e1422. doi:10.4314/orapj.v7i3.22
BibTeX
@article{Ntambwe2026,
author = {Ntambwe and M., N. and Kabamb and D, K. and Mana and D., K. and Marini and R, D. and Mbinze and J, K.},
title = {The Substandard and falsified medicines in the Democratic Republic of the Congo: Situational analysis and future perspectives},
journal = {Orapuh Journal},
year = {2026},
volume = {7},
number = {3},
pages = {e1422},
doi = {10.4314/orapj.v7i3.22}
}
EUVIMED